 |
|
 |
|
       |
|
|
|
|
|
|
|
Biotech Venture Capital Directory
The following is a list of some venture capital companies who focus either exclusively or in part on the healthcare/biotech/biomedical area.
3i invest in a wide range of opportunities from start-ups to buy-outs and buy-ins, focusing on those with high growth potential and strong management.
|
|
Abingworth is a long-established venture capital firm specialising in unquoted and life science biomedical companies. With offices in London, Cambridge (UK) and Palo Alto.
|
|
Founded in 1981, Advent Venture Partners claims to be one of the first US-style venture capital firms in Europe. With over £500m of fund commitments under management, their focus is on venture and growth investment in two sectors: Life Sciences and Technology.
|
|
Alta Partners is a venture capital firm in life sciences, funding over 130 companies in the industry since 1996. It claims a diverse and integrated team bringing together a depth of knowledge and experience, delivering tangible results.
|
|
Amadeus Capital Partners Limited is a venture capital company specialising in high-technology investments in the UK and Europe. Offices in London and Cambridge.
|
|
Apax Partners is an independent global private equity advisory firm. Funds advised by Apax Partners (‘Apax Funds’) typically invest in companies with a value of between €1bn and €5bn.
|
|
ARCH Venture Partners invests in the development of seed and early stage technology companies that have the potential to grow rapidly into successful businesses. ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences, physical sciences, and information technology.
|
|
Atlas Venture invests primarily in early stage technology and life sciences businesses in the U.S. and Europe.
|
|
Since its incorporation, Avonmore has become active in sub- £1million seed and early stage capital financing.
|
|
Burrill & Company is a life sciences merchant bank focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology (biomaterials/bioprocesses) - and has over $950 million under management.
|
|
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2.5 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA. Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics.
|
|
Founded in 1988 as Hambro European Ventures, the company was bought out from Hambros in 1998 and the name changed to Duke Street Capital.Offices in London and Paris. Duke Street invests in 14 companies in six sectors, with a combined turnover of €2 billion and employs over 30,000 staff. Total number of investments is 45 in 20 years.
|
|
ECI is one of the longest established private equity groups in the UK, specialising in buyouts, buy-ins and development capital deals between £5 and £100 million. Offices based in Manchester and London.
|
|
ETCapital invests in high-growth companies exploiting the innovative application of technology. Offices are based in Cambridge.
|
|
Excalibur Fund Managers is a specialised venture investor in life sciences companies managing and advising three funds, worth in excess of €450 million of equity capital. Excalibur invests in companies that are bringing to market human medicines or medical devices with groundbreaking technology and significant commercial potential.
|
|
Flagship Ventures is a venture capital firm focused on creating, financing and building innovative companies. Founded in 2000, Flagship manages over $600 million in early-stage funds and operates from its offices at Kendall Square in Cambridge, MA. With an active portfolio of over 40 companies, the firm’s strategy is to balance its investments across three principal business sectors: Therapeutics, Life Science Tools & Diagnostics, and BioEnergy/Cleantech
|
|
Gresham is a leading independent UK mid-market private equity specialist. Focusing on management buy-outs up to £100m, it invests across a broad range of businesses throughout the UK.
|
|
Graphite Capital is a leading private equity investor focused on the auk mid-market. The company has raised and managed private equity funds since 1981 and became independent in 2001. It manages more than £1.2 billion of funds for institutional and private shareholders. Its most recent fund raised £555 million in May 2007.
|
|
HealthCare Ventures is a leading venture capital firm specializing in life science industry investing. It focuses on life science companies showing high growth potential.
|
|
ICG is a fully independent UK public company which is listed on the London Stock Exchange and the group is dedicated to providing mezzanine capital in Europe and Asia Pacific.
|
|
InterWest Partners is a diversified venture capital firm based in Silicon Valley.
|
|
IPSO Ventures creates commercial value from intellectual property and technology generated by universities and other research institutions both in the UK and worldwide.
|
|
Since its founding in 1972, Kleiner Perkins Caufield & Byers has backed entrepreneurs in over 600 ventures. KPCB portfolio companies employ more than 250,000 people. More than 150 of the firm's portfolio companies have gone public.
|
|
LDC has invested over £1billion in the past five years and has a current portfolio of 68 core investments valued in excess of £2.8billion. Since 1981 LDC has completed over 400 investments
|
|
London Seed Capital Limited (LSC) is a seed and early-stage venture capital fund. London Seed Capital was established as a co-investment fund, which means that LSC only invests where its investment is at least matched by business angels. It can invest a maximum of £100,000 in the first round, alongside a minimum of £100,000 of business angel investment. LSC operates in conjunction with the London Business Angel network (LBA) .
|
|
Longbow specialises in the early stage, development and expansion phases of the growth of unquoted companies.
|
|
Mtf is an investment fund focused on providing early-stage equity funding to help create new university spin-out companies.
|
|
MPM Capital claims to be one of the world's largest life science-dedicated venture investors. With committed capital under management in excess of $2 billion, MPM Capital invests globally in healthcare innovation.
|
|
MTI is an independent venture capital fund manager with a remit to provide risk capital and management resources to British high technology companies that are at an early stage of their development or recovery.
|
|
NESTA is the National Endowment for Science, Technology and the Arts. Its mission to make the UK more innovative. It invests in early-stage companies, inform and shape policy, and deliver practical programmes that inspire others to solve the big challenges of the future.
|
|
NEA often leads early-stage equity rounds, with a typical initial investment of $3-10 million and the ability to participate in every stage of investment at full pro-rata or above.
|
|
Oxford Capital Partners is focused on the following sectors: biotechnology, medical technologies, healthcare, nanotechnology, materials technologies, environmental technologies etc.
|
|
OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. |
|
Polaris Venture Partners is a partnership of venture capital investors and technology executives. Its mission is to identify and invest in seed, first round, and early stage information technology and life science businesses with exceptional promise and help them grow into sustainable, market-leading companies.
|
|
Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads investments across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services.
|
|
Quester is one of the UK's leading independent venture capital groups specialising in the provision of finance and management support for growth companies at all stages of their life. Now renamed Spark
|
|
Founded in 1979, Sanderling is among the oldest investment firms dedicated to building new biomedical companies.
|
|
SEP is one of Europe's leadingventure capital firms. As well as backing start up and early stage businesses, it also invests in more established companies looking to use venture capital to build scale and momentum.
|
|
Sofinnova Ventures has over 30 years of experience building start-ups and spin-outs into market leaders. With $1 billion under management, the firm applies capital and expertise to guide early stage companies to successful exits.
|
|
Sovereign Capital is a successful UK mid-market private equity investor. Independent, it invests equity in proven management teams, committed to growing their businesses. Offices in London.
|
|
Spark Ventures is one of the UK's leading independent venture capital groups specialising in the provision of finance and management support for growth companies at all stages of their life. Renamed from Quester.
|
|
The Summit Group is a privately owned independent venture capital business which invests in start ups and early stage businesses.
|
|
SV Life Sciences is a venture capital adviser and manager that makes selected investments in businesses with experienced entrepreneurs and management teams. SV Life Sciences provides finance to businesses at all stages of development and across the human life sciences sector
|
|
The capital fund is a venture capital fund backing fast-growing, small and medium enterprises (SMEs) in Greater London.
|
|
Top Technology Ventures is an independent UK-based venture capital company which specialises in providing equity funding for early stage technology based growth companies.
|
|
TTP Ventures provides venture capital for early stage science and technology companies based in the UK and other Western European countries.
|
|
UCL Angels looks to invest at an early-stage in interesting new companies that typically have a strong technology and intellectual property base that can enable them to become dominant players in their chosen markets. UCL Angels provides financing and mentoring from its pool of experienced entrepreneurs and small company managers.
|
|
Venrock is a premier venture capital firm with offices in Palo Alto, New York, Cambridge, MA, and Israel. Originally established as the venture capital arm of the Rockefeller family, Venrock continues an eight-decade tradition of partnering with entrepreneurs to establish successful, enduring companies.
|
|
Warburg Pincus is a global leader in private Equity. With more than 40 years experience, it claims investment of more than $29 billion in more than 600 companies in 30 countries around the world. |
October 2009
